CL2007003491A1 - CRYSTALLINE FORM OF ACID (3S) -3- [N- (N- (2-TERCBUTILFENIL) OXAMIL) ALANINIL] AMINO-5 (23,5,6-TETRAFLUOROFENOXI) -4-OXOPENTANOICO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND ITS USE TO TREAT HEPATIC FIBROSIS. - Google Patents
CRYSTALLINE FORM OF ACID (3S) -3- [N- (N- (2-TERCBUTILFENIL) OXAMIL) ALANINIL] AMINO-5 (23,5,6-TETRAFLUOROFENOXI) -4-OXOPENTANOICO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND ITS USE TO TREAT HEPATIC FIBROSIS.Info
- Publication number
- CL2007003491A1 CL2007003491A1 CL200703491A CL2007003491A CL2007003491A1 CL 2007003491 A1 CL2007003491 A1 CL 2007003491A1 CL 200703491 A CL200703491 A CL 200703491A CL 2007003491 A CL2007003491 A CL 2007003491A CL 2007003491 A1 CL2007003491 A1 CL 2007003491A1
- Authority
- CL
- Chile
- Prior art keywords
- tetrafluorofenoxi
- tercbutilfenil
- oxopentanoico
- alaninil
- oxamil
- Prior art date
Links
- 206010019668 Hepatic fibrosis Diseases 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- KZAUOCCYDRDERY-UHFFFAOYSA-N oxamyl Chemical compound CNC(=O)ON=C(SC)C(=O)N(C)C KZAUOCCYDRDERY-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86874806P | 2006-12-06 | 2006-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007003491A1 true CL2007003491A1 (en) | 2008-06-20 |
Family
ID=39205161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200703491A CL2007003491A1 (en) | 2006-12-06 | 2007-12-04 | CRYSTALLINE FORM OF ACID (3S) -3- [N- (N- (2-TERCBUTILFENIL) OXAMIL) ALANINIL] AMINO-5 (23,5,6-TETRAFLUOROFENOXI) -4-OXOPENTANOICO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND ITS USE TO TREAT HEPATIC FIBROSIS. |
Country Status (23)
Country | Link |
---|---|
US (1) | US7692038B2 (en) |
EP (1) | EP2091910B1 (en) |
JP (1) | JP5495787B2 (en) |
KR (1) | KR101125932B1 (en) |
CN (3) | CN103951583B (en) |
AR (1) | AR064809A1 (en) |
AU (1) | AU2007330478B2 (en) |
CA (1) | CA2669849C (en) |
CL (1) | CL2007003491A1 (en) |
DK (1) | DK2091910T3 (en) |
ES (1) | ES2524021T3 (en) |
HK (3) | HK1138567A1 (en) |
HN (1) | HN2007000536A (en) |
IL (1) | IL198732A (en) |
MX (1) | MX2009006055A (en) |
NO (1) | NO338908B1 (en) |
PA (1) | PA8759501A1 (en) |
PE (1) | PE20081251A1 (en) |
PL (1) | PL2091910T3 (en) |
PT (1) | PT2091910E (en) |
TW (1) | TWI345466B (en) |
UY (1) | UY30758A1 (en) |
WO (1) | WO2008068615A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE030969T2 (en) * | 2010-02-12 | 2017-06-28 | Pfizer | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
CN103113405B (en) * | 2012-10-17 | 2016-03-02 | 上海日馨生物科技有限公司 | Benfotiamine polymorphs body, preparation method and application thereof |
KR20240010105A (en) * | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | Pharmaceutical compositions of therapeutically active compounds |
KR20170015312A (en) | 2014-05-12 | 2017-02-08 | 코나터스 파마슈티칼스, 인크. | Treatment of the complications of chronic liver disease with caspase inhibitors |
ES2975633T3 (en) * | 2014-09-08 | 2024-07-10 | Pfizer | Solid crystalline forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicine |
NZ734041A (en) * | 2015-01-30 | 2022-02-25 | Vertex Pharma | Crystalline forms of c21h22cl2n4o2 |
EP3265440A1 (en) | 2015-03-06 | 2018-01-10 | Concert Pharmaceuticals Inc. | Deuterated emricasan |
CN105017061B (en) * | 2015-07-07 | 2017-03-29 | 苏州富士莱医药股份有限公司 | A kind of synthetic method of ENBREL card life |
WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
WO2017117478A1 (en) | 2015-12-31 | 2017-07-06 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
US20190231770A1 (en) | 2016-10-05 | 2019-08-01 | Novartis Ag | Combination compositions comprising fxr agonists for treating or preventing a fibrotic, cirrhotic disease or disorder |
CN113354708B (en) * | 2017-01-23 | 2024-05-14 | 正大天晴药业集团股份有限公司 | Bicyclic compounds as Caspase inhibitors |
WO2018172950A1 (en) * | 2017-03-23 | 2018-09-27 | Novartis Ag | Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate |
AU2018246255B2 (en) * | 2017-03-30 | 2021-07-08 | Merck Patent Gmbh | Crystalline form of (s)-(2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl)-(6-methoxy-pyridazin-3-yl)-methanol |
AR114251A1 (en) * | 2018-02-13 | 2020-08-12 | Syngenta Participations Ag | CRYSTALLINE FORMS OF N- [2- (2,4-DICHLOROPHENYL) CYCLOBUTIL] -2- (TRIFLUOROMETL) PYRIDIN-3-CARBOXAMIDE |
CA3105352A1 (en) | 2018-06-29 | 2020-01-02 | Histogen, Inc. | (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
US11597703B2 (en) | 2019-03-07 | 2023-03-07 | Histogen, Inc. | Caspase inhibitors and methods of use thereof |
CN111351780A (en) * | 2019-12-29 | 2020-06-30 | 中船重工(邯郸)派瑞特种气体有限公司 | Analysis method for electrolyte components in trifluoromethyl sulfonyl fluoride electrolytic cell |
WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2100291T3 (en) * | 1991-07-30 | 1997-06-16 | Ajinomoto Kk | CRYSTALS OF N- (TRANS-4-ISOPROPILCICLOHEXILCARBONIL) -D-PHENYLALANINE AND METHODS TO PREPARE THEM. |
ES2105003T3 (en) * | 1993-05-12 | 1997-10-16 | Heumann Pharma Gmbh & Co | STABLE AND CRYSTALLINE FORM OF THE BEZAFIBRATE. |
US6197750B1 (en) * | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6544951B2 (en) * | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US7053056B2 (en) * | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
GB9923933D0 (en) * | 1999-10-08 | 1999-12-08 | Smithkline Beecham Lab | Novel pharmaceutical |
AU2002349538B2 (en) * | 2001-12-11 | 2006-04-27 | Kyorin Pharmaceutical Co., Ltd. | Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same |
WO2007007162A1 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
-
2007
- 2007-12-03 WO PCT/IB2007/003900 patent/WO2008068615A1/en active Application Filing
- 2007-12-03 MX MX2009006055A patent/MX2009006055A/en active IP Right Grant
- 2007-12-03 CN CN201410058519.5A patent/CN103951583B/en active Active
- 2007-12-03 ES ES07859033.8T patent/ES2524021T3/en active Active
- 2007-12-03 CN CN201410057544.1A patent/CN103923169B/en not_active Expired - Fee Related
- 2007-12-03 JP JP2009539823A patent/JP5495787B2/en active Active
- 2007-12-03 AU AU2007330478A patent/AU2007330478B2/en not_active Ceased
- 2007-12-03 DK DK07859033.8T patent/DK2091910T3/en active
- 2007-12-03 CA CA2669849A patent/CA2669849C/en active Active
- 2007-12-03 KR KR1020097011692A patent/KR101125932B1/en active IP Right Grant
- 2007-12-03 CN CN200780045311.8A patent/CN101573328B/en active Active
- 2007-12-03 PT PT78590338T patent/PT2091910E/en unknown
- 2007-12-03 EP EP07859033.8A patent/EP2091910B1/en active Active
- 2007-12-03 PL PL07859033T patent/PL2091910T3/en unknown
- 2007-12-04 UY UY30758A patent/UY30758A1/en not_active Application Discontinuation
- 2007-12-04 CL CL200703491A patent/CL2007003491A1/en unknown
- 2007-12-04 HN HN2007000536A patent/HN2007000536A/en unknown
- 2007-12-04 PA PA20078759501A patent/PA8759501A1/en unknown
- 2007-12-05 PE PE2007001720A patent/PE20081251A1/en not_active Application Discontinuation
- 2007-12-05 TW TW096146304A patent/TWI345466B/en active
- 2007-12-05 AR ARP070105447A patent/AR064809A1/en not_active Application Discontinuation
- 2007-12-06 US US11/951,801 patent/US7692038B2/en active Active
-
2009
- 2009-05-13 IL IL198732A patent/IL198732A/en active IP Right Grant
- 2009-05-14 NO NO20091892A patent/NO338908B1/en not_active IP Right Cessation
-
2010
- 2010-05-03 HK HK10104322.9A patent/HK1138567A1/en not_active IP Right Cessation
-
2015
- 2015-01-07 HK HK15100168.9A patent/HK1199885A1/en not_active IP Right Cessation
- 2015-01-23 HK HK15100810.1A patent/HK1200440A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003491A1 (en) | CRYSTALLINE FORM OF ACID (3S) -3- [N- (N- (2-TERCBUTILFENIL) OXAMIL) ALANINIL] AMINO-5 (23,5,6-TETRAFLUOROFENOXI) -4-OXOPENTANOICO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND ITS USE TO TREAT HEPATIC FIBROSIS. | |
BRPI0816553A2 (en) | "compound, pharmaceutical composition, use of a composition, use of a compound, and process for the preparation of a compound" | |
CL2007001972A1 (en) | ISOPROPILIC ESTER OF THE ACID 4- [6- (6-METHANOSULPHONYL-2-METHYLPIRIDIN-3-ILAMINO) -5-METHYL-PYRIMIDIN-4-ILOXI] PIPERIDIN-1-CARBOXILIC, METABOLISM MODULATORS; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT METABOLIC DISORDERS. | |
CL2009000882A1 (en) | A compound n- (4-chloro-3- (pyridin-2-yl) phenyl) -4- (2-hydroxy-2-methylpropylsulfonyl) -2-methylbenzamide, inhibitor of the hedgehog signaling pathway; pharmaceutical composition comprising said compound; and its use to treat cancer. | |
BRPI0818533A2 (en) | compound, pharmaceutical composition, and process for the preparation of a compound | |
CL2007001759A1 (en) | METFORMIN COMPOUND R - (+) LIPOATE; MIXTING THAT METFORMIN AND ACID R - (+) LIPOIC; PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMPOUND; METHOD FOR PREPARING THE COMPOUND; KIT; AND USE TO TREAT DIABETES. | |
CL2007002446A1 (en) | COMPOUNDS DERIVED FROM MORFOLINO PIRIMIDINA; PHARMACEUTICAL COMPOSITION; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO PRODUCE AN ANTIPROLIFERING EFFECT. | |
BRPI0814593A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND. | |
CL2008000197A1 (en) | COMPOUNDS DERIVED FROM 2,4-DIAMINO PIRIMIDINA, ANTRANILAMIDE INHIBITORS OF CINASA AURORA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT CANCER. | |
CL2008000094A1 (en) | COMPOUNDS DERIVED FROM PTERIDINE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO INCREASE VASODILATATION. | |
CL2007001325A1 (en) | COMPOUNDS DERIVED FROM BICYCLES, CEPT INHIBITORS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT HYPERLIPIDEMIA, ARTERIOESCLEROSIS, AMONG OTHER ILLNESSES. | |
CL2007002641A1 (en) | COMPOUNDS DERIVED FROM PYRIMIDINS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF ALLERGIC DISORDERS, AUTOIMMUNES, INFLAMMATORY DISEASES. | |
CL2007003423A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED PYRIMIDINS; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF Rheumatoid ARTHRITIS, ATEROSCLEROSIS, AMONG OTHER DISEASES | |
MA30236B1 (en) | NEW PHARMACEUTICAL COMPOSITION | |
BRPI0808293A2 (en) | "compositions for nasal administration" | |
CL2008001002A1 (en) | COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION. | |
CL2007002916A1 (en) | COMPOUNDS DERIVED FROM PIRAZOLILTIENOPIRIDINAS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE INHIBITION OF ESCARAS. | |
CL2008001868A1 (en) | COMPOUNDS DERIVED FROM N- (2- (HETARIL) ARIL) ARILSULPHONAMIDS AND N- (2- (HETARIL) HETARIL) ARILSULFONAMIDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE INTESTINE, ALLERGIC DISEASE | |
BRPI0809667A2 (en) | COMPOUND, MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND | |
CL2007003232A1 (en) | COMPOUNDS DERIVED FROM 5-HYDROXIMETHYL OXAZOLIDIN-2-ONA; PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPOUNDS; AND ITS USE TO TREAT AND PREVENT BACTERIAL INFECTIONS. | |
CL2008000784A1 (en) | AMINO-5 COMPOUNDS - [- 4- (DIFLOUROMETOXI) SUBSTITUTED PHENYL] -5-PHENYLMIDAZOLONE, B-SECRETASE INHIBITORS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT ALZHEIMER, COGNITIVE DETERIORATION, DOWN SYNDROME, DECREASE CO | |
BRPI0912539A2 (en) | compound, pharmaceutical composition, method for treating a disease, and use of the compound. | |
CL2007002021A1 (en) | COMPOUNDS DERIVED FROM OXOISOINDOL; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM; AND ITS USE TO TREAT ARRITMIAS. | |
BRPI0815360A2 (en) | 4-PYRIMIDINOSULFAMIDE DERIVATIVE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING IT, USE AND PROCESS FOR PAIR PREPARATION | |
CL2007001838A1 (en) | COMPOUNDS DERIVED FROM 4-OXOQUINOLINE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE PRODUCTION OF AN ANTI-HIV AGENT. |